Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year

Pediatrics

Volumn 124, Issue 5, 2009, Pages 1333-1343

  Watson, R Scott ^a   Clermont, Gilles ^a   Kinsella, John P ^b   Kong, Lan ^a,c   Arendt, Robert E ^d,e   Cutter, Gary ^f   Linde Zwirble, Walter T ^g   Abman, Steven H ^b   Angus, Derek C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g ZD Associates   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Controlled trial; Health care costs; Inhaled nitric oxide; Intraventricular hemorrhage; Long term effects; Prematurity; Quality adjusted survival; Randomized; Respiratory distress syndrome

Indexed keywords

NITRIC OXIDE; OXYGEN; PLACEBO;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; ECONOMIC ASPECT; EXPERIENCE; FEMALE; GESTATIONAL AGE; HEALTH CARE UTILIZATION; HOSPITAL BILLING; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; INTERVIEW; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NERVE CELL DIFFERENTIATION; NEUROLOGIC EXAMINATION; NEWBORN; NEWBORN PERIOD; PREMATURITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FAILURE; SURVIVAL; TELEPHONE;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DEVELOPMENTAL DISABILITIES; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NEUROLOGIC EXAMINATION; NITRIC OXIDE; QUALITY OF LIFE; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 70350516052     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-0114     Document Type: Article

References (49)

1. Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355(4):354-364 (Pubitemid 44127538)
2. Kanwar S, Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. New Horiz. 1995;3(1):93-104
3. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res. 1994;36(3):402-408
4. Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res. 1997;41(4 pt 1):457-463 (Pubitemid 27147859)
5. Gutierrez HH, Nieves B, Chumley P, Rivera A, Freeman BA. Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med. 1996;21(1):43-52 (Pubitemid 26230404)
6. Ballard PL, Merrill JD, Truog WE, et al. Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics. 2007;120(2):346-353 (Pubitemid 47219505)
7. Ballard PL, Gonzales LW, Godinez RI, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res. 2006;59(1):157-162 Jan
8. Gong X, Guo C, Huang S, Sun B. Inhaled nitric oxide alleviates hyperoxia suppressed phosphatidylcholine synthesis in endotoxininduced injury in mature rat lungs. Respir Res. 2006;7:5 (Pubitemid 43285547)
9. McCurnin DC, Pierce RA, Chang LY, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol. 2005;288(3):L450-L459
10. Lin YJ, Markham NE, Balasubramaniam V, et al. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res. 2005;58(1):22-29 (Pubitemid 40967424)
11. Bland RD, Albertine KH, Carlton DP, MacRitchie AJ. Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs. Am J Respir Crit Care Med. 2005;172(7):899-906
12. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597-604
13. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469-474 (Pubitemid 30100234)
14. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med. 2003;349(22):2099-2107 (Pubitemid 37464534)
15. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343-353 (Pubitemid 44127537)
16. Kinsella JP, Walsh WF, Bose CL, et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999;354(9184):1061-1065 (Pubitemid 29452817)
17. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353(1):13-22 (Pubitemid 41007803)
18. Whittle J, Lin CJ, Lave JR, et al. Relationship of provider characteristics to outcomes, process, and costs of care for communityacquired pneumonia. Med Care. 1998;36(7):977-987 (Pubitemid 128456437)
19. Ellis SG, Miller DP, Brown KJ, et al. In-hospital cost of percutaneous coronary revascularization: critical determinants and implications. Circulation. 1995;92(4):741-747
20. Rogowski J, Harrison E. Treatment Costs for Very Low Birth Weight Infants. Santa Monica, CA: Rand Corporation; 1995. Report No. MR-451-AHCPR
21. Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(6):1389-1394 (Pubitemid 32506604)
22. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89-102 (Pubitemid 23113445)
23. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics. 2003;112(6 pt 1):1351-1360 (Pubitemid 37523419)
24. Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004;114(2):417-426 (Pubitemid 39006670)
25. Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birth weight 500-999 g born in Victoria in the post surfactant era. J Paediatr Child Health. 1997;33(3):202-208
26. Saigal S, Stoskopf BL, Feeny D, et al. Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents. JAMA. 1999;281(21):1991-1997 (Pubitemid 29254856)
27. Oostenbrink R, Maas M, Moons KG, Moll HA. Sequelae after bacterial meningitis in childhood. Scand J Infect Dis. 2002;34(5):379-382
28. Feeny D, Furlong W, Torrance GW, et al. Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113-128
29. Bureau of Labor Statistics. Unpublished Tabulations From the Current Population Survey, 2000. Washington, DC: Bureau of Labor Statistics; 2000
30. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 1996
31. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
32. Angus DC, Rubenfeld GD, Roberts MS, et al. Understanding costs and cost-effectiveness in critical care: report from the Second American Thoracic Society Workshop on Outcomes Research. Am J Respir Crit Care Med. 2002;165(4):540-550
33. Consumer Price Indexes. US Department of Labor, Bureau of Labor Statistics. Available at: www.bls.gov/cpi/home.htm. Accessed October 25, 2008
34. Hintz SR, Van Meurs KP, Perritt R, et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized, controlled trial of inhaled nitric oxide. J Pediatr. 2007;151(1):16-22 (Pubitemid 46935185)
35. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353(1):23-32 (Pubitemid 41007804)
36. Owens PL, Thompson J, Elixhauser A, Ryan K. Care of Children and Adolescents in US Hospitals. Rockville, MD: Agency for Healthcare Research and Quality; 2003. Agency for Healthcare Research and Quality publication No 04-10004
37. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613
38. Prentice RL. Surrogate end points in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431-440 (Pubitemid 19105891)
39. High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants: assessment of pulmonary function at 9 months of corrected age. HiFi Study Group. J Pediatr. 1990;116(6):933-941
40. Garland JS, Alex CP, Pauly TH, et al. A 3-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics. 1999;104(1 pt 1):91-99
41. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83(3):F177-F181 (Pubitemid 30825793)
42. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 pt 1):15-21
43. Holling EE, Leviton A. Characteristics of cranial ultrasound white-matter echolucencies that predict disability: a review. Dev Med Child Neurol. 1999;41(2):136-139 (Pubitemid 29074082)
44. Pierrat V, Duquennoy C, van HI, Ernst M, Guilley N, de Vries LS. Ultrasound diagnosis and neurodevelopmental outcome of localised and extensive cystic periventricular leucomalacia. Arch Dis Child Fetal Neonatal Ed. 2001;84(3):F151-F156 (Pubitemid 32411251)
45. O'Shea TM, Klinepeter KL, Dillard RG. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol. 1998;147(4):362-369
46. Ment LR, Vohr B, Allan W, et al. Change in cognitive function over time in very low-birth-weight infants. JAMA. 2003;289(6):705-711 (Pubitemid 37430364)
47. Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5):1305-1311 (Pubitemid 41647693)
48. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: How good a basis for estimating costs? Inquiry. 1995;32(4):476-481 (Pubitemid 26164225)
49. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194 (Pubitemid 350146117)